SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-172425
Filing Date
2022-06-13
Accepted
2022-06-13 07:16:55
Documents
13
Period of Report
2022-06-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d358853d8k.htm   iXBRL 8-K 26721
2 EX-99.1 d358853dex991.htm EX-99.1 19215
  Complete submission text file 0001193125-22-172425.txt   178973

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amlx-20220613.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20220613_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20220613_pre.xml EX-101.PRE 11706
7 EXTRACTED XBRL INSTANCE DOCUMENT d358853d8k_htm.xml XML 3463
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 221010691
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences